The 50% fall in the market and COVID-19 mark TUBACEX’s results
The sales figure for the first half of the year amounts to €282 M, down 12.8% on the same period last year, and the EBITDA stands at €19.8 M, 40.5% less. These figures are a far cry from TUBACEX’s prospects at the start of the year but, even in such an unfavorable...TUBACEX holds its Annual Shareholders’ General Meeting overshadowed by COVID-19
The company reveals the main points of its strategy in response to the pandemic. With a focus on prevention, the aim is to guarantee the safety of all its workers, and thereby service continuity for its customers. TUBACEX has dealt with this crisis from a solid...TUBACEX presents its results in a market context dominated by COVID-19
2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.
TUBACEX announces consolidated results and ends 2019 with an EBITDA of €67.1 million
2019 has marked a turning point for recovery as TUBACEX order intake demonstrates. Although far from pre-crisis levels it has experienced an increase of 30% in relation to the previous year. This gradual and general market recovery is also enabling operating leverage ratios to be maintained for all business units and therefore, achieving double-digit consolidated margins.
